Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped up before the market opened on Friday . The stock had previously closed at $22.49, but opened at $24.1250. Chugai Pharmaceutical shares last traded at $24.1750, with a volume of 12,926 shares changing hands.

Chugai Pharmaceutical Stock Up 7.7%

The firm has a market cap of $79.71 billion, a price-to-earnings ratio of 30.28 and a beta of 0.64. The company’s 50-day moving average price is $23.04 and its 200-day moving average price is $24.30.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Friday, October 24th. The company reported $0.23 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 32.74% and a return on equity of 20.63%. The firm had revenue of $2.26 billion during the quarter. Analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.